Targeting SLC7A5 in lung squamous cell carcinoma: implications for cancer metabolism shift and boron neutron capture therapy resistance
Таргетирование SLC7A5 при плоскоклеточном раке лёгкого: значение для перестройки метаболизма опухоли и устойчивости к бор-нейтронозахватной терапии
2025-07-23
SCID: 54.1/kqvukc7m
Discuss with AI
BPA-BNCT resistanceSLC7A5autophagyboron neutron capture therapylung squamous cell carcinoma
Figures from the paper
Abstract (AI)
Squamous cell carcinoma (SCC) poses a significant global health challenge due to the lack of effective treatments. Boron neutron capture therapy (BNCT), a targeted particle therapy, has shown promising results in various cancers. SLC7A5, a transporter of essential amino acids and boronophenylalanine (BPA) used in BNCT, emerges as a potential therapeutic target. However, its expression across different histological subtypes and the role of SLC7A5 inhibition in developing drug resistance to BPA-BNCT remain poorly understood. Our study reveals elevated SLC7A5 expression in most SCCs, particularly in lung squamous cell carcinoma (LUSC), where it is significantly higher compared to other lung cancer subtypes. Increased SLC7A5 expression and a higher tumor-to-normal (T/N) ratio in LUSC are associated with poor patient prognosis. SLC7A5 knockdown in LUSC cells reduces colony formation and induces apoptosis. RNA-seq analysis of SLC7A5 knockout LUSC cells shows downregulated mTORC1 signaling, reduced expression of other amino acid transporters, and upregulated autophagy genes, indicating a potential cancer metabolic shift. Furthermore, SLC7A5 knockout LUSC cells demonstrate resistance to BPA-BNCT but sensitivity to the autophagy inhibitor chloroquine. Post-BPA-BNCT treatment, surviving wild-type LUSC cells exhibit reduced SLC7A5 levels and increased sensitivity to chloroquine, highlighting a vulnerability in BPA-BNCT-resistant cells. Our findings elucidate the interplay between SLC7A5, mTOR signaling, and autophagy pathways, providing insights into potential strategies to overcome drug resistance in BPA-BNCT therapy.
Key Findings
1
Higher SLC7A5 expression and tumor-to-normal ratios in lung squamous cell carcinoma are associated with poorer patient prognosis.
2
SLC7A5 is elevated across most squamous cell carcinomas and is particularly overexpressed in lung squamous cell carcinoma compared with other lung cancer subtypes.
3
SLC7A5 knockdown reduces lung squamous carcinoma colony formation and induces apoptosis, supporting its role in tumor cell survival.
4
SLC7A5 knockout confers resistance to BPA-BNCT but increases sensitivity to chloroquine; BPA-BNCT-surviving cells similarly show reduced SLC7A5 and chloroquine vulnerability.
5
SLC7A5 loss suppresses mTORC1 signaling, decreases other amino acid transporters, and increases autophagy-related genes, indicating a metabolic shift.
Research Object
SLC7A5-expressing lung squamous cell carcinoma cells and tumors
Research Subject
The effects of SLC7A5 inhibition on cancer metabolism, mTORC1 signaling, autophagy, and resistance to BPA-BNCT
Publication Details
Publication Date
2025-07-23
Journal
Publisher
ISSN
Cited by
6
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest